Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 bladder cancer study

More than 614,000 new cases of the disease are diagnosed globally every year

- PMLiVE

Novo Nordisk shares positive results for Mim8 in late-stage haemophilia A trial

The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

US researchers develop 3D technique to identify precancerous pancreatic lesions

PanIN lesions can lead to invasive ductal adenocarcinoma, which affects nearly half a million people globally

- PMLiVE

Alnylam presents positive late-stage results for RNAi therapeutic in ATTR with cardiomyopathy

Hereditary ATTR and wild-type ATTR are responsible for an estimated 350,000 cases globally

- PMLiVE

P-AI-n or g-AI-n?

Who will win in an AI-coloured world?

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

- PMLiVE

FDA approves argenx’s Vyvgart Hytrulo for rare neuromuscular disorder CIDP

Approximately 24,000 US patients are currently being treated for chronic inflammatory demyelinating polyneuropathy

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

- PMLiVE

ISID establishes six global infectious disease priorities to be addressed at 2024 congress

Involving health and community leaders, the ISID congress will commence in South Africa in December

- PMLiVE

Pharma’s content conundrum

With consistency problems, quantity and quality needs and HCP overload, it’s time to take content even more seriously

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links